Opportunity ID: 189274

General Information

Document Type:: Grants Notice
Funding Opportunity Number:: RFA-RM-12-014
Funding Opportunity Title:: Clinical Utility of Extracellular RNA for Therapy Development (UH2/UH3)
Opportunity Category:: Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity:: Health
Category Explanation::
Expected Number of Awards::
Assistance Listings Number(s):: 93.310 — Trans-NIH Research Support
Cost Sharing or Matching Requirement:: No
Version:: Synopsis 1
Posted Date:: Aug 03, 2012
Last Updated Date::
Original Closing Date for Applications:: Nov 13, 2012
Current Closing Date for Applications:: Nov 13, 2012
Archive Date:: Dec 14, 2012
Estimated Total Program Funding::
Award Ceiling:: $
Award Floor:: $

Eligibility

Eligible Applicants:: State governments
Additional Information on Eligibility:: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name:: National Institutes of Health
Description:: Extracellular RNA (exRNA) is present in human body fluids, such as blood, saliva, urine, breast milk, amniotic fluid, cerebrospinal fluid, ascites and pleural effusions. The concept that secreted exRNA can alter target cell phenotypes is emerging as a universal and novel paradigm in intercellular signaling. In view of this emerging paradigm, the NIH invites applications for projects that will develop novel therapies based on exRNA signaling. The overall goal of this initiative is to develop and demonstrate the potential for clinical utility of exRNAs as therapeutic agents, and to develop tools and technologies to enable engineered RNAs to be packaged into extracellular vesicles or associated with RNA-binding proteins for use as extracellular delivery vehicles. These projects should include methods for the production, purification, and packaging of specific RNAs and methods to deliver them to target cells via extracellular space.
Link to Additional Information::
Grantor Contact Information:: If you have difficulty accessing the full announcement electronically, please contact:

Version History

Version Modification Description Updated Date
Synopsis 1

Package Status

Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:

Package No: 1

Assistance Listings: 93.310
Competition ID: ADOBE-FORMS-B2
Competition Title: ADOBE-FORMS-B2
Opportunity Package ID: PKG00136452
Opening Date: Oct 12, 2012
Closing Date: Nov 13, 2012
Agency Contact Information:: Grants Info
Who Can Apply:: Organization Applicants
mendatory_forms SF424 (R & R) [V1.2]
Project/Performance Site Location(s) [V1.4]
Research And Related Other Project Information [V1.3]
Research And Related Senior/Key Person Profile (Expanded) [V1.2]
Research & Related Budget [V1.1]
PHS 398 Cover Page Supplement [V1.4]
PHS 398 Research Plan [V1.3]
PHS 398 Checklist [V1.3]
optional_forms R & R Subaward Budget Attachment(s) Form 5 YR 30 ATT [V1.2]
PHS Cover Letter [V1.2]

Packages

Assistance Listings Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions Who Can Apply:
93.310 ADOBE-FORMS-B2 ADOBE-FORMS-B2 PKG00136452 Oct 12, 2012 Nov 13, 2012 View Grants Info Organization Applicants